secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2021-08-09T23:59:59+00:00
Accession:  0000950170-21-001072
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022
--------------------------------------------------------------------------------

- Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.
- Cash and equivalents $880.9M; royalty financing from BBA capped at $450M after second $125M tranche not paid.
- Phase 3 wet AMD DAZZLE study on track topline data Q1 2022; enrollment in BEACON, GLEAM, GLIMMER, DAYLIGHT ongoing.
- China IND approved for KSI-301 in RVO and DME; first patients expected in 2021.
- Proposed INN for KSI-301 is tarcocimab tedromer; GLOW study in non-proliferative DR to start August 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/0000950170-21-001072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/kod-20210809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer